Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?

被引:7
作者
Infante, Mar [1 ]
Arranz-Ledo, Monica [1 ]
Lastra, Enrique [2 ]
Abella, Luis Enrique [3 ]
Ferreira, Raquel [3 ]
Orozco, Marta [3 ]
Hernandez, Lara [1 ]
Martinez, Noemi [1 ]
Duran, Mercedes [1 ]
机构
[1] Univ Valladolid Spanish, Excellence Unit Inst Biol & Mol Genet, UVa CSIC, Canc Genet Grp,Natl Res Council IBGM, C Sanz & Fores 3, Valladolid 47003, Spain
[2] Burgos Univ Hosp, Unit Genet Counseling Canc, Burgos 09006, Spain
[3] Rio Hortega Univ Hosp, Unit Genet Counseling Canc, Valladolid 47012, Spain
关键词
Hereditary Breast and Ovarian Cancer Syndrome (HBOC); Lynch Syndrome (LS); multi-gene panel testing; double heterozygotes; genetic counseling; FAMILIAL BREAST; MUTATIONS; RAD51C; BRCA1;
D O I
10.3390/ijms231911499
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The probability of carrying two pathogenic variants (PVs) in dominant cancer-predisposing genes for hereditary breast and ovarian cancer and lynch syndromes in the same patient is uncommon, except in populations where founder effects exist. Two breast cancer women that are double heterozygotes (DH) for both BRCA1/BRCA2, one ovarian cancer case DH for BRCA1/RAD51C, and another breast and colorectal cancer who is DH for BRCA2/PMS2 were identified in our cohort. Ages at diagnosis and severity of disease in BRCA1/BRCA2 DH resembled BRCA1 single-carrier features. Similarly, the co-existence of the BRCA2 and PMS2 mutations prompted the development of breast and colorectal cancer in the same patient. The first BRCA1/BRCA2 DH was identified by HA-based and Sanger sequencing (1 of 623 families with BRCA PVs). However, this ratio has increased up to 2.9% (1 DH carrier vs. 103 single PV carriers) since using a custom 35-cancer gene on-demand panel. The type of cancer developed in each DH patient was consistent with the independently inherited condition, and the clinical outcome was no worse than in patients with single BRCA1 mutations. Therefore, the clinical impact, especially in patients with two hereditary syndromes, lies in genetic counseling tailor-made for each family based on the clinical guidelines for each syndrome. The number of DH is expected to be increased in the future as a result of next generation sequencing routines.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Co-occurrence of breast cancer and neuroendocrine tumours: New genetic insights beyond Multiple Endocrine Neoplasia syndromes
    Larouche, Vincent
    Akirov, Amit
    Thain, Emily
    Kim, Raymond H.
    Ezzat, Shereen
    [J]. ENDOCRINOLOGY DIABETES & METABOLISM, 2019, 2 (04)
  • [22] Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer
    Rachel A. Pozzar
    Fangxin Hong
    Niya Xiong
    Jill E. Stopfer
    Manan M. Nayak
    Meghan Underhill-Blazey
    [J]. Familial Cancer, 2022, 21 : 35 - 47
  • [23] Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer
    Pozzar, Rachel A.
    Hong, Fangxin
    Xiong, Niya
    Stopfer, Jill E.
    Nayak, Manan M.
    Underhill-Blazey, Meghan
    [J]. FAMILIAL CANCER, 2022, 21 (01) : 35 - 47
  • [24] Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome
    Shaw, Josephine
    Bulsara, Caroline
    Cohen, Paul A.
    Gryta, Madeleine
    Nichols, Cassandra B.
    Schofield, Lyn
    O'Sullivan, Sarah
    Pachter, Nicholas
    Hardcastle, Sarah J.
    [J]. PATIENT EDUCATION AND COUNSELING, 2018, 101 (05) : 938 - 944
  • [25] Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome
    Yoo, Jaeeun
    Lee, Gun Dong
    Kim, Jee Hae
    Lee, Seung Nam
    Chae, Hyojin
    Han, Eunhee
    Kim, Yonggoo
    Kim, Myungshin
    [J]. ANNALS OF LABORATORY MEDICINE, 2020, 40 (02) : 152 - 158
  • [26] Detection of BRCA1 Pathogenic Variant in a 24-Year-Old Endometrial Cancer Patient: Risks of Several Hereditary Tumor Syndromes Assessed Using Germline Multigene Panel Testing
    Wang, Xiaofei
    Kaneko, Keika
    Arakawa, Hiromi
    Habano, Eri
    Omi, Makiko
    Nakashima, Eri
    Kawachi, Hiroshi
    Tonooka, Akiko
    Omatsu, Kohei
    Nomura, Hidetaka
    Yunokawa, Mayu
    Kanao, Hiroyuki
    Takahashi, Shunji
    Nakajima, Takeshi
    Ueki, Arisa
    [J]. CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 792 - 797
  • [27] Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center
    Chapman-Davis, Eloise
    Zhou, Zhen Ni
    Fields, Jessica C.
    Frey, Melissa K.
    Jordan, Bailey
    Sapra, Katherine J.
    Chatterjee-Paer, Sudeshna
    Carlson, Ann D.
    Holcomb, Kevin M.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (01) : 35 - 42
  • [28] Genetic Testing in Hereditary Breast and Ovarian Cancer Using Massive Parallel Sequencing
    Ruiz, Anna
    Llort, Gemma
    Yaguee, Carmen
    Baena, Neus
    Vinas, Marina
    Torra, Montse
    Brunet, Anna
    Segui, Miquel A.
    Saigi, Eugeni
    Guitart, Miriam
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [29] Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer
    Szender, J. Brian
    Kaur, Jasmine
    Clayback, Katherine
    Hutton, Mollie L.
    Mikkelson, June
    Odunsi, Kunle
    Dresbold, Cara
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 26 - 33
  • [30] Influence of Race/Ethnicity on Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer
    Forman, Andrea D.
    Hall, Michael J.
    [J]. BREAST JOURNAL, 2009, 15 : S56 - S62